CLINICAL TRIALS PROFILE FOR COPIKTRA
✉ Email this page to a colleague
All Clinical Trials for Copiktra
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03961672 ↗ | Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2020-05-13 | This phase II trial studies how well duvelisib on an intermittent (irregular) dosing schedule works in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving duvelisib on an intermittent schedule may result in similar effectiveness with less amount of severe side effects. |
| NCT03961672 ↗ | Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Recruiting | City of Hope Medical Center | Phase 2 | 2020-05-13 | This phase II trial studies how well duvelisib on an intermittent (irregular) dosing schedule works in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving duvelisib on an intermittent schedule may result in similar effectiveness with less amount of severe side effects. |
| NCT03961672 ↗ | Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Recruiting | OHSU Knight Cancer Institute | Phase 2 | 2020-05-13 | This phase II trial studies how well duvelisib on an intermittent (irregular) dosing schedule works in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving duvelisib on an intermittent schedule may result in similar effectiveness with less amount of severe side effects. |
| NCT04193293 ↗ | A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | Suspended | SecuraBio | Phase 1/Phase 2 | 2020-02-25 | This study will assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in subjects with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). |
| NCT04193293 ↗ | A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | Suspended | Verastem, Inc. | Phase 1/Phase 2 | 2020-02-25 | This study will assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in subjects with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Copiktra
Condition Name
| Condition Name for Copiktra | |
| Intervention | Trials |
| COVID-19 | 2 |
| Head and Neck Squamous Cell Carcinoma | 1 |
| Recurrent Nodal Marginal Zone Lymphoma | 1 |
| Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for Copiktra
Trials by Country
Clinical Trial Progress for Copiktra
Clinical Trial Phase
Clinical Trial Sponsors for Copiktra
Sponsor Name
